Pfizer (PFE) Consolidated Net Income (2009 - 2026)
Pfizer (PFE) posted quarterly Consolidated Net Income of -$13.0 million for Q1 2026, down 152.0% quarter-over-quarter from $25.0 million in Q2 2025.
Pfizer (PFE) Consolidated Net Income (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Consolidated Net Income for 18 consecutive years, with -$13.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Consolidated Net Income changed N/A year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 33.33% YoY), while the FY2025 annual figure was $25.0 million, up 127.27% from the prior year.
- Consolidated Net Income declined to -$13.0 million in Q1 2026 per PFE's latest filing, from $25.0 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $34.0 million in Q3 2022 and bottomed at -$26.0 million in Q4 2023.
- Historically, Consolidated Net Income has averaged $1.4 million across 5 years, with a median of -$3.5 million in 2023.
- Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 1000.0% — and 2024, when it soared 950.0%.
- Pfizer's Consolidated Net Income stood at $34.0 million in 2022, then plunged by 176.47% to -$26.0 million in 2023, then jumped by 69.23% to -$8.0 million in 2024, then surged by 412.5% to $25.0 million in 2025, then slumped by 152.0% to -$13.0 million in 2026.
- Business Quant data shows PFE's Consolidated Net Income at -$13.0 million in Q1 2026, $25.0 million in Q2 2025, and -$8.0 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 8.00 Mn |
| Mar 29, 2026 | -13.00 Mn |
| Jun 29, 2025 | 25.00 Mn |
| Sep 29, 2024 | -8.00 Mn |
| Jun 30, 2024 | 17.00 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Jul 2, 2023 | -2.00 Mn |
| Apr 2, 2023 | 1.00 Mn |
| Jul 3, 2022 | 34.00 Mn |
| Apr 3, 2022 | -9.00 Mn |
| Oct 3, 2021 | -248.00 Mn |
| Jul 4, 2021 | -236.00 Mn |
| Apr 4, 2021 | 1.00 Mn |
| Sep 27, 2020 | 2.33 Bn |
| Jun 28, 2020 | 893.00 Mn |
| Mar 29, 2020 | 881.00 Mn |
| Dec 31, 2019 | 5.31 Bn |
| Sep 29, 2019 | 4.00 Mn |
| Dec 31, 2018 | 7.32 Bn |